Literature DB >> 9874675

Anticytomegalovirus (anti-CMV) immunoglobulin G avidity in identification of pregnant women at risk of transmitting congenital CMV infection.

T Lazzarotto1, P Spezzacatena, S Varani, L Gabrielli, P Pradelli, B Guerra, M P Landini.   

Abstract

In this work, we show that the determination of the anticytomegalovirus antibody avidity carried out before week 18 of gestation is a helpful tool to identify women for enrollment in prenatal diagnosis. This procedure can identify all pregnant women who will give birth to an infected newborn.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 9874675      PMCID： PMC95671          DOI： 10.1128/CDLI.6.1.127-129.1999

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN： 1071-412X


  17 in total

1.  Avidity of immunoglobulin G directed against human cytomegalovirus during primary and secondary infections in immunocompetent and immunocompromised subjects.

Authors:  T Lazzarotto; P Spezzacatena; P Pradelli; D A Abate; S Varani; M P Landini
Journal:  Clin Diagn Lab Immunol       Date:  1997-07

Review 2.  Epidemiology of cytomegalovirus infections.

Authors:  M Ho
Journal:  Rev Infect Dis       Date:  1990 Sep-Oct

3.  Value of cytomegalovirus (CMV) IgG avidity index for the diagnosis of primary CMV infection in pregnant women.

Authors:  L Grangeot-Keros; M J Mayaux; P Lebon; F Freymuth; G Eugene; R Stricker; E Dussaix
Journal:  J Infect Dis       Date:  1997-04       Impact factor: 5.226

4.  Rapid detection of cytomegalovirus in MRC-5 cells inoculated with urine specimens by using low-speed centrifugation and monoclonal antibody to an early antigen.

Authors:  C A Gleaves; T F Smith; E A Shuster; G R Pearson
Journal:  J Clin Microbiol       Date:  1984-06       Impact factor: 5.948

5.  An enzyme labelled nuclear antigen immunoassay for detection of cytomegalovirus IgM antibodies in human serum: specific and non-specific reactions.

Authors:  C M Nielsen; K Hansen; H M Andersen; J Gerstoft; B F Vestergaard
Journal:  J Med Virol       Date:  1987-05       Impact factor: 2.327

Review 6.  Treatment of viral infections during pregnancy and the neonatal period.

Authors:  R J Whitley; D W Kimberlin
Journal:  Clin Perinatol       Date:  1997-03       Impact factor: 3.430

7.  IgM antibody detection of ppUL80A and ppUL32 by immunoblotting: an early parameter for recurrent cytomegalovirus infection in renal transplant recipients.

Authors:  Y J Kraat; F S Stals; M H Christiaans; T Lazzarotto; M P Landini; C A Bruggeman
Journal:  J Med Virol       Date:  1996-03       Impact factor: 2.327

8.  Pattern of anti-cytomegalovirus IgM antibodies determined by immunoblotting. A study of kidney graft recipients developing a primary or recurrent CMV infection.

Authors:  J Basson; J C Tardy; M Aymard
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

9.  Congenital cytomegalovirus infection: The relative importance of primary and recurrent maternal infection.

Authors:  S Stagno; R F Pass; M E Dworsky; R E Henderson; E G Moore; P D Walton; C A Alford
Journal:  N Engl J Med       Date:  1982-04-22       Impact factor: 91.245

10.  Prenatal diagnosis of congenital cytomegalovirus infection.

Authors:  T Lazzarotto; B Guerra; P Spezzacatena; S Varani; L Gabrielli; P Pradelli; F Rumpianesi; C Banzi; L Bovicelli; M P Landini
Journal:  J Clin Microbiol       Date:  1998-12       Impact factor: 5.948
View more
  19 in total

1.  Validation of an in-house assay for cytomegalovirus immunoglobulin G (CMV IgG) avidity and relationship of avidity to CMV IgM levels.

Authors:  Harry E Prince; Amy L Leber
Journal:  Clin Diagn Lab Immunol       Date:  2002-07

2.  Evaluation of a cytomegalovirus glycoprotein B recombinant enzyme immunoassay to discriminate between a recent and a past infection.

Authors:  M J Sipewa; P Goubau; M Bodéus
Journal:  J Clin Microbiol       Date:  2002-10       Impact factor: 5.948

3.  Multicenter evaluation of a rapid and convenient method for determination of cytomegalovirus immunoglobulin G avidity.

Authors:  M Baccard-Longere; F Freymuth; D Cointe; J M Seigneurin; L Grangeot-Keros
Journal:  Clin Diagn Lab Immunol       Date:  2001-03

4.  Potential impact of different cytomegalovirus (CMV) IgM assays on an algorithm requiring IgM reactivity as a criterion for measuring CMV IgG avidity.

Authors:  Harry E Prince; Mary Lapé-Nixon; Andrew Brenner; Nancy Pitstick; Marc Roger Couturier
Journal:  Clin Vaccine Immunol       Date:  2014-03-26

5.  Performance of a cytomegalovirus IgG enzyme immunoassay kit modified to measure avidity.

Authors:  Harry E Prince; Mary Lapé-Nixon; Susan M Novak-Weekley
Journal:  Clin Vaccine Immunol       Date:  2014-03-26

6.  Analytical issues possibly affecting the performance of commercial human cytomegalovirus IgG avidity assays.

Authors:  M Berth; L Grangeot-Keros; F Heskia; J-M Dugua; C Vauloup-Fellous
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-04-30       Impact factor: 3.267

Review 7.  The "silent" global burden of congenital cytomegalovirus.

Authors:  Sheetal Manicklal; Vincent C Emery; Tiziana Lazzarotto; Suresh B Boppana; Ravindra K Gupta
Journal:  Clin Microbiol Rev       Date:  2013-01       Impact factor: 26.132

8.  Evaluation of the Abbott AxSYM cytomegalovirus (CMV) immunoglobulin M (IgM) assay in conjunction with other CMV IgM tests and a CMV IgG avidity assay.

Authors:  T Lazzarotto; C Galli; R Pulvirenti; R Rescaldani; R Vezzo; A La Gioia; C Martinelli; S La Rocca; G Agresti; L Grillner; M Nordin; M van Ranst; B Combs; G T Maine; M P Landini
Journal:  Clin Diagn Lab Immunol       Date:  2001-01

Review 9.  Role of cytomegalovirus (CMV) IgG avidity testing in diagnosing primary CMV infection during pregnancy.

Authors:  Harry E Prince; Mary Lapé-Nixon
Journal:  Clin Vaccine Immunol       Date:  2014-08-27

10.  The role of maternal screening in diagnosing congenital cytomegalovirus infections in highly immune populations.

Authors:  F Şahiner; M Honca; Y Çekmez; A Kubar; T Honca; M K Fidanci; T Purtuloğlu; M Yapar
Journal:  Ir J Med Sci       Date:  2014-06-04       Impact factor: 1.568
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.